scholarly journals Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD

Author(s):  
Yang Ying ◽  
Chen Shuang ◽  
Zhang Zhen‐Ying
1979 ◽  
Vol 41 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Hiroshi MACHINO ◽  
Tomoyuki KAWATSU ◽  
Yoshiharu MIKI

JRSM Open ◽  
2021 ◽  
Vol 12 (2) ◽  
pp. 205427042098145
Author(s):  
Bindi Gaglani ◽  
Ian Logan ◽  
Faris Kubba

Reactive perforating collagenosis is commonly recognised as an unusual form of transepithelial elimination of collagen and elastin fibres which are extruded through the epidermis in patients with a genetic predisposition or underlying diseases, such as diabetes mellitus or renal diseases. We present the unusual case of an 87-year-old diabetic male with a giant form of reactive perforating collagenosis and review the available literature.


Author(s):  
Diego Arancibia Tagle ◽  
Jose Carlos Neves ◽  
Alwyn D'Souza

AbstractThe correction and management of the nasal hump has been a classic problem in rhinoplasty since the beginning of the aesthetic purpose of this surgery. For many years, the resective technique described by Joseph has been the battle horse to solve this problem but it has several drawbacks if not done properly. In the late 19th and early 20th centuries, a new dorsal conservative technique was born and for several years was an alternative option to treat the same problem without damaging the keystone area while preserving the dorsal connection between the upper lateral cartilage and the septum. The aim of this article is to review the history and evolution of this technique, which has been reborn after several years, and how it has evolved since then.


2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Binrong Ye ◽  
Yi Cao ◽  
Yeqiang Liu

Abstract Background Acquired reactive perforating collagenosis (ARPC) is a rare form of transepithelial elimination in which altered collagen is extruded through the epidermis. Case presentation A 23-year-old male presented with cup-like ulcerated lesions on his limbs since 3 months. A series of serological and immunological tests showed no abnormalities. A diagnosis of ARPC was based on skin biopsy findings. The patient was cured using treatment with itraconazole for 8 weeks, in the absence of a fungal infection. Conclusions The anti-inflammatory and anti-angiogenic effects of itraconazole can have good therapeutic benefits for ARPC.


Author(s):  
Nao Kusutani ◽  
Sakurako Arai ◽  
Akiko Imanishi ◽  
Naoki Maekawa ◽  
Kazuyoshi Fukai

2019 ◽  
Vol 34 (5) ◽  
pp. 791-794
Author(s):  
Kirsten A Riggan ◽  
Megan Allyse

1985 ◽  
Vol 113 (s29) ◽  
pp. 44-45
Author(s):  
E. Young ◽  
F. Wojnarowska ◽  
P. Millard

Sign in / Sign up

Export Citation Format

Share Document